Annual report

Period2022-01-01 → 2022-12-31

Filed2023-03-27

StandardJapan GAAP

ConsolidatedYes

Data checks24 of 24 passed

Key figures · 137

Metric	Value	Period	Scope	Source row
Revenue	¥1.4bn	2022-01-01 → 2022-12-31	Cons.	Net sales
Revenue	¥2.0bn	2021-01-01 → 2021-12-31	Cons.	Net sales
Revenue	¥1.1bn	2020-01-01 → 2020-12-31^d	Cons.	Net sales (5-year summary)
Revenue	¥3.2bn	2019-01-01 → 2019-12-31^d	Cons.	Net sales (5-year summary)
Revenue	¥755m	2018-01-01 → 2018-12-31^d	Cons.	Net sales (5-year summary)
Operating income	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Operating income
Operating income	−¥531m	2021-01-01 → 2021-12-31	Cons.	Operating income
Ordinary income	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Ordinary income
Ordinary income	−¥523m	2021-01-01 → 2021-12-31	Cons.	Ordinary income
Ordinary income	−¥1.1bn	2020-01-01 → 2020-12-31^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	¥957m	2019-01-01 → 2019-12-31^d	Cons.	Ordinary income loss (5-year summary)
Ordinary income	−¥1.2bn	2018-01-01 → 2018-12-31^d	Cons.	Ordinary income loss (5-year summary)
Profit before tax	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Income before income taxes
Profit before tax	−¥532m	2021-01-01 → 2021-12-31	Cons.	Income before income taxes
Net income (owners)	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥534m	2021-01-01 → 2021-12-31	Cons.	Profit loss attributable to owners of parent
Net income (owners)	−¥1.1bn	2020-01-01 → 2020-12-31^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	¥828m	2019-01-01 → 2019-12-31^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income (owners)	−¥1.2bn	2018-01-01 → 2018-12-31^d	Cons.	Profit loss attributable to owners of parent (5-year summary)
Net income	−¥1.3bn	2022-01-01 → 2022-12-31	Cons.	Profit loss
Net income	−¥534m	2021-01-01 → 2021-12-31	Cons.	Profit loss
Total assets	¥4.3bn	at 2022-12-31	Cons.	Assets
Total assets	¥5.4bn	at 2021-12-31	Cons.	Assets
Total assets	¥4.8bn	at 2020-12-31^d	Cons.	Total assets (5-year summary)
Total assets	¥5.4bn	at 2019-12-31^d	Cons.	Total assets (5-year summary)
Total assets	¥1.8bn	at 2018-12-31^d	Cons.	Total assets (5-year summary)
Total liabilities	¥625m	at 2022-12-31	Cons.	Liabilities
Total liabilities	¥1.1bn	at 2021-12-31	Cons.	Liabilities
Net assets / equity	¥3.6bn	at 2022-12-31	Cons.	Net assets
Net assets / equity	¥4.3bn	at 2021-12-31	Cons.	Net assets
Net assets / equity	¥3.8bn	at 2020-12-31^d	Cons.	Net assets
Net assets / equity	¥3.9bn	at 2019-12-31^d	Cons.	Net assets (5-year summary)
Net assets / equity	¥887m	at 2018-12-31^d	Cons.	Net assets (5-year summary)
Cash and deposits	¥3.4bn	at 2022-12-31	Cons.	Cash and deposits
Cash and deposits	¥3.8bn	at 2021-12-31	Cons.	Cash and deposits
Cash & equivalents	¥3.4bn	at 2022-12-31	Cons.	Cash and cash equivalents
Cash & equivalents	¥3.8bn	at 2021-12-31	Cons.	Cash and cash equivalents
Cash & equivalents	¥4.3bn	at 2020-12-31^d	Cons.	Cash and cash equivalents
Cash & equivalents	¥4.9bn	at 2019-12-31^d	Cons.	Cash and cash equivalents (5-year summary)
Cash & equivalents	¥1.4bn	at 2018-12-31^d	Cons.	Cash and cash equivalents (5-year summary)
Operating cash flow	−¥708m	2022-01-01 → 2022-12-31	Cons.	Net cash provided by used in operating activities
Operating cash flow	−¥1.5bn	2021-01-01 → 2021-12-31	Cons.	Net cash provided by used in operating activities
Operating cash flow	−¥1.3bn	2020-01-01 → 2020-12-31^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	¥1.5bn	2019-01-01 → 2019-12-31^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Operating cash flow	−¥1.1bn	2018-01-01 → 2018-12-31^d	Cons.	Net cash provided by used in operating activities (5-year summary)
Investing cash flow	−¥126m	2022-01-01 → 2022-12-31	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥42m	2021-01-01 → 2021-12-31	Cons.	Net cash provided by used in investment activities
Investing cash flow	−¥70m	2020-01-01 → 2020-12-31^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥41m	2019-01-01 → 2019-12-31^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Investing cash flow	−¥58m	2018-01-01 → 2018-12-31^d	Cons.	Net cash provided by used in investing activities (5-year summary)
Financing cash flow	¥367m	2022-01-01 → 2022-12-31	Cons.	Net cash provided by used in financing activities
Financing cash flow	¥1.1bn	2021-01-01 → 2021-12-31	Cons.	Net cash provided by used in financing activities
Financing cash flow	¥724m	2020-01-01 → 2020-12-31^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	¥2.1bn	2019-01-01 → 2019-12-31^d	Cons.	Net cash provided by used in financing activities (5-year summary)
Financing cash flow	¥688m	2018-01-01 → 2018-12-31^d	Cons.	Net cash provided by used in financing activities (5-year summary)
EPS (basic)	¥-99.1	2022-01-01 → 2022-12-31	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-42.1	2021-01-01 → 2021-12-31	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-90.33	2020-01-01 → 2020-12-31^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥76.05	2019-01-01 → 2019-12-31^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-125.02	2018-01-01 → 2018-12-31^d	Cons.	Basic earnings loss per share (5-year summary)
EPS (diluted)	¥74.51	2019-01-01 → 2019-12-31^d	Cons.	Diluted earnings per share (5-year summary)
Net assets per share	¥255.04	at 2022-12-31	Cons.	Net assets per share (5-year summary)
Net assets per share	¥323.54	at 2021-12-31	Cons.	Net assets per share (5-year summary)
Net assets per share	¥308.05	at 2020-12-31^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥329.86	at 2019-12-31^d	Cons.	Net assets per share (5-year summary)
Net assets per share	¥86.83	at 2018-12-31^d	Cons.	Net assets per share (5-year summary)
Equity ratio	85.0%	at 2022-12-31	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	79.3%	at 2021-12-31	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	79.0%	at 2020-12-31^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	71.5%	at 2019-12-31^d	Cons.	Equity to asset ratio (5-year summary)
Equity ratio	49.7%	at 2018-12-31^d	Cons.	Equity to asset ratio (5-year summary)
ROE	35.1%	2019-01-01 → 2019-12-31^d	Cons.	Rate of return on equity (5-year summary)
Employees	65	at 2022-12-31	Cons.	Number of employees
Employees	64	at 2021-12-31	Cons.	Number of employees
Employees	64	at 2020-12-31^d	Cons.	Number of employees
Employees	63	at 2019-12-31^d	Cons.	Number of employees
Employees	62	at 2018-12-31^d	Cons.	Number of employees
Revenue	¥1.2bn	2022-01-01 → 2022-12-31	Standalone	Net sales
Revenue	¥1.9bn	2021-01-01 → 2021-12-31	Standalone	Net sales
Revenue	¥1.0bn	2020-01-01 → 2020-12-31^d	Standalone	Net sales (5-year summary)
Revenue	¥3.1bn	2019-01-01 → 2019-12-31^d	Standalone	Net sales (5-year summary)
Revenue	¥641m	2018-01-01 → 2018-12-31^d	Standalone	Net sales (5-year summary)
Operating income	−¥1.3bn	2022-01-01 → 2022-12-31	Standalone	Operating income
Operating income	−¥558m	2021-01-01 → 2021-12-31	Standalone	Operating income
Ordinary income	−¥1.4bn	2022-01-01 → 2022-12-31	Standalone	Ordinary income
Ordinary income	−¥549m	2021-01-01 → 2021-12-31	Standalone	Ordinary income
Ordinary income	−¥1.1bn	2020-01-01 → 2020-12-31^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥874m	2019-01-01 → 2019-12-31^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	−¥1.2bn	2018-01-01 → 2018-12-31^d	Standalone	Ordinary income loss (5-year summary)
Profit before tax	−¥1.4bn	2022-01-01 → 2022-12-31	Standalone	Income before income taxes
Profit before tax	−¥558m	2021-01-01 → 2021-12-31	Standalone	Income before income taxes
Net income	−¥1.4bn	2022-01-01 → 2022-12-31	Standalone	Profit loss
Net income	−¥556m	2021-01-01 → 2021-12-31	Standalone	Profit loss
Net income	−¥1.1bn	2020-01-01 → 2020-12-31^d	Standalone	Net income loss (5-year summary)
Net income	¥746m	2019-01-01 → 2019-12-31^d	Standalone	Net income loss (5-year summary)
Net income	−¥1.2bn	2018-01-01 → 2018-12-31^d	Standalone	Net income loss (5-year summary)
Total assets	¥4.0bn	at 2022-12-31	Standalone	Assets
Total assets	¥5.3bn	at 2021-12-31	Standalone	Assets
Total assets	¥4.7bn	at 2020-12-31^d	Standalone	Total assets (5-year summary)
Total assets	¥5.3bn	at 2019-12-31^d	Standalone	Total assets (5-year summary)
Total assets	¥1.8bn	at 2018-12-31^d	Standalone	Total assets (5-year summary)
Total liabilities	¥607m	at 2022-12-31	Standalone	Liabilities
Total liabilities	¥1.1bn	at 2021-12-31	Standalone	Liabilities
Net assets / equity	¥3.4bn	at 2022-12-31	Standalone	Net assets
Net assets / equity	¥4.2bn	at 2021-12-31	Standalone	Net assets
Net assets / equity	¥3.7bn	at 2020-12-31^d	Standalone	Net assets
Net assets / equity	¥3.8bn	at 2019-12-31^d	Standalone	Net assets (5-year summary)
Net assets / equity	¥900m	at 2018-12-31^d	Standalone	Net assets (5-year summary)
Cash and deposits	¥3.1bn	at 2022-12-31	Standalone	Cash and deposits
Cash and deposits	¥3.6bn	at 2021-12-31	Standalone	Cash and deposits
EPS (basic)	¥-103.2	2022-01-01 → 2022-12-31	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-43.83	2021-01-01 → 2021-12-31	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-91.84	2020-01-01 → 2020-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥68.47	2019-01-01 → 2019-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥-123.85	2018-01-01 → 2018-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (diluted)	¥67.08	2019-01-01 → 2019-12-31^d	Standalone	Diluted earnings per share (5-year summary)
Net assets per share	¥240.82	at 2022-12-31	Standalone	Net assets per share (5-year summary)
Net assets per share	¥314.45	at 2021-12-31	Standalone	Net assets per share (5-year summary)
Net assets per share	¥301.39	at 2020-12-31^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥323.68	at 2019-12-31^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥88.07	at 2018-12-31^d	Standalone	Net assets per share (5-year summary)
Equity ratio	84.6%	at 2022-12-31	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	78.9%	at 2021-12-31	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	78.7%	at 2020-12-31^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	71.1%	at 2019-12-31^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	50.1%	at 2018-12-31^d	Standalone	Equity to asset ratio (5-year summary)
ROE	32.0%	2019-01-01 → 2019-12-31^d	Standalone	Rate of return on equity (5-year summary)
Shares issued	14,218,300	at 2022-12-31	Standalone	Total number of issued shares (5-year summary)
Shares issued	13,313,400	at 2021-12-31	Standalone	Total number of issued shares (5-year summary)
Shares issued	12,407,100	at 2020-12-31^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	11,654,500	at 2019-12-31^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	10,139,600	at 2018-12-31^d	Standalone	Total number of issued shares (5-year summary)
Employees	62	at 2022-12-31	Standalone	Number of employees
Employees	61	at 2021-12-31	Standalone	Number of employees
Employees	61	at 2020-12-31^d	Standalone	Number of employees
Employees	60	at 2019-12-31^d	Standalone	Number of employees
Employees	58	at 2018-12-31^d	Standalone	Number of employees

Periods use the dates stated in the filing. ^d = earlier-year period dated by calendar; ^v = that date confirmed by the company's own earlier filing.

Segments · 42

Segment	Item	Period	Value
Reconciling Itemsreconciling	segment assets	at 2022-12-31	¥3.2bn
Drug Discovery Businessreportable segment	capex	2022-01-01 → 2022-12-31	¥68m
Drug Discovery Businessreportable segment	depreciation	2022-01-01 → 2022-12-31	¥13m
Drug Discovery Businessreportable segment	employees	at 2022-12-31	34 pure
Drug Discovery Businessreportable segment	revenue	2022-01-01 → 2022-12-31	¥286m
Drug Discovery Businessreportable segment	revenue external	2022-01-01 → 2022-12-31	¥286m
Drug Discovery Businessreportable segment	segment assets	at 2022-12-31	¥373m
Drug Discovery Businessreportable segment	segment profit	2022-01-01 → 2022-12-31	−¥1.7bn
Drug Discovery Support Businessreportable segment	capex	2022-01-01 → 2022-12-31	¥58m
Drug Discovery Support Businessreportable segment	depreciation	2022-01-01 → 2022-12-31	¥21m
Drug Discovery Support Businessreportable segment	employees	at 2022-12-31	23 pure
Drug Discovery Support Businessreportable segment	revenue	2022-01-01 → 2022-12-31	¥1.1bn
Drug Discovery Support Businessreportable segment	revenue external	2022-01-01 → 2022-12-31	¥1.1bn
Drug Discovery Support Businessreportable segment	segment assets	at 2022-12-31	¥685m
Drug Discovery Support Businessreportable segment	segment profit	2022-01-01 → 2022-12-31	¥453m
—segment total	capex	2022-01-01 → 2022-12-31	¥126m
—segment total	depreciation	2022-01-01 → 2022-12-31	¥34m
—segment total	revenue	2022-01-01 → 2022-12-31	¥1.4bn
—segment total	revenue external	2022-01-01 → 2022-12-31	¥1.4bn
—segment total	segment assets	at 2022-12-31	¥1.1bn
—segment total	segment profit	2022-01-01 → 2022-12-31	−¥1.3bn
Reconciling Itemsreconciling	segment assets	at 2021-12-31	¥3.7bn
Drug Discovery Businessreportable segment	capex	2021-01-01 → 2021-12-31	¥14m
Drug Discovery Businessreportable segment	depreciation	2021-01-01 → 2021-12-31	¥5m
Drug Discovery Businessreportable segment	revenue	2021-01-01 → 2021-12-31	¥1.1bn
Drug Discovery Businessreportable segment	revenue external	2021-01-01 → 2021-12-31	¥1.1bn
Drug Discovery Businessreportable segment	segment assets	at 2021-12-31	¥1.2bn
Drug Discovery Businessreportable segment	segment profit	2021-01-01 → 2021-12-31	−¥820m
Drug Discovery Support Businessreportable segment	capex	2021-01-01 → 2021-12-31	¥12m
Drug Discovery Support Businessreportable segment	depreciation	2021-01-01 → 2021-12-31	¥15m
Drug Discovery Support Businessreportable segment	revenue	2021-01-01 → 2021-12-31	¥890m
Drug Discovery Support Businessreportable segment	revenue external	2021-01-01 → 2021-12-31	¥890m
Drug Discovery Support Businessreportable segment	segment assets	at 2021-12-31	¥497m
Drug Discovery Support Businessreportable segment	segment profit	2021-01-01 → 2021-12-31	¥289m
—segment total	capex	2021-01-01 → 2021-12-31	¥26m
—segment total	depreciation	2021-01-01 → 2021-12-31	¥19m
—segment total	revenue	2021-01-01 → 2021-12-31	¥2.0bn
—segment total	revenue external	2021-01-01 → 2021-12-31	¥2.0bn
—segment total	segment assets	at 2021-12-31	¥1.7bn
—segment total	segment profit	2021-01-01 → 2021-12-31	−¥531m
Drug Discovery Businessreportable segment	employees	at 2022-12-31	33 pure
Drug Discovery Support Businessreportable segment	employees	at 2022-12-31	21 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,303

Item	Context	Value	Unit
Net cash provided by used in financing activities (5-year summary)	Prior1YearDuration	1064987000	JPY
Net cash provided by used in financing activities (5-year summary)	CurrentYearDuration	367006000	JPY
Cash and cash equivalents (5-year summary)	Prior4YearInstant	1355254000	JPY
Cash and cash equivalents (5-year summary)	Prior3YearInstant	4915056000	JPY
Cash and cash equivalents (5-year summary)	Prior2YearInstant	4299142000	JPY
Cash and cash equivalents (5-year summary)	Prior1YearInstant	3817834000	JPY
Cash and cash equivalents (5-year summary)	CurrentYearInstant	3379048000	JPY
Number of employees	Prior4YearInstant	62
Number of employees	Prior3YearInstant	63
Number of employees	Prior2YearInstant	64
Number of employees	Prior1YearInstant	64
Number of employees	CurrentYearInstant	65
Average number of temporary workers	Prior4YearInstant	2
Average number of temporary workers	Prior3YearInstant	4
Average number of temporary workers	Prior2YearInstant	4
Average number of temporary workers	Prior1YearInstant	9
Average number of temporary workers	CurrentYearInstant	8
Net sales (5-year summary)	Prior4YearDuration_NonConsolidatedMember	640711000	JPY
Net sales (5-year summary)	Prior3YearDuration_NonConsolidatedMember	3070843000	JPY
Net sales (5-year summary)	Prior2YearDuration_NonConsolidatedMember	1042960000	JPY
Net sales (5-year summary)	Prior1YearDuration_NonConsolidatedMember	1931718000	JPY
Net sales (5-year summary)	CurrentYearDuration_NonConsolidatedMember	1216066000	JPY
Ordinary income loss (5-year summary)	Prior4YearDuration_NonConsolidatedMember	-1156637000	JPY
Ordinary income loss (5-year summary)	Prior3YearDuration_NonConsolidatedMember	874478000	JPY
Ordinary income loss (5-year summary)	Prior2YearDuration_NonConsolidatedMember	-1096348000	JPY
Ordinary income loss (5-year summary)	Prior1YearDuration_NonConsolidatedMember	-548843000	JPY
Ordinary income loss (5-year summary)	CurrentYearDuration_NonConsolidatedMember	-1357020000	JPY
Net income loss (5-year summary)	Prior4YearDuration_NonConsolidatedMember	-1199225000	JPY
Net income loss (5-year summary)	Prior3YearDuration_NonConsolidatedMember	745709000	JPY
Net income loss (5-year summary)	Prior2YearDuration_NonConsolidatedMember	-1129612000	JPY
Net income loss (5-year summary)	Prior1YearDuration_NonConsolidatedMember	-556425000	JPY
Net income loss (5-year summary)	CurrentYearDuration_NonConsolidatedMember	-1405357000	JPY
Capital stock (5-year summary)	Prior4YearInstant_NonConsolidatedMember	3591568000	JPY
Capital stock (5-year summary)	Prior3YearInstant_NonConsolidatedMember	4657466000	JPY
Capital stock (5-year summary)	Prior2YearInstant_NonConsolidatedMember	558829000	JPY
Capital stock (5-year summary)	Prior1YearInstant_NonConsolidatedMember	1056953000	JPY
Capital stock (5-year summary)	CurrentYearInstant_NonConsolidatedMember	1382246000	JPY
Total number of issued shares (5-year summary)	Prior4YearInstant_NonConsolidatedMember	10139600
Total number of issued shares (5-year summary)	Prior3YearInstant_NonConsolidatedMember	11654500
Total number of issued shares (5-year summary)	Prior2YearInstant_NonConsolidatedMember	12407100
Total number of issued shares (5-year summary)	Prior1YearInstant_NonConsolidatedMember	13313400
Total number of issued shares (5-year summary)	CurrentYearInstant_NonConsolidatedMember	14218300
Net assets (5-year summary)	Prior4YearInstant_NonConsolidatedMember	900044000	JPY
Net assets (5-year summary)	Prior3YearInstant_NonConsolidatedMember	3781463000	JPY
Net assets (5-year summary)	Prior2YearInstant_NonConsolidatedMember	3741428000	JPY
Net assets (5-year summary)	Prior1YearInstant_NonConsolidatedMember	4194643000	JPY
Net assets (5-year summary)	CurrentYearInstant_NonConsolidatedMember	3439714000	JPY
Total assets (5-year summary)	Prior4YearInstant_NonConsolidatedMember	1780565000	JPY
Total assets (5-year summary)	Prior3YearInstant_NonConsolidatedMember	5302570000	JPY
Total assets (5-year summary)	Prior2YearInstant_NonConsolidatedMember	4748867000	JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed

balance sheet identity	consolidated 2021-12-31	pass
balance sheet identity	consolidated 2022-12-31	pass
balance sheet identity	non_consolidated 2021-12-31	pass rounding
balance sheet identity	non_consolidated 2022-12-31	pass
dei present		pass
period resolution		pass
statement vs summary · net assets	consolidated 2020-12-31	pass
statement vs summary · net assets	consolidated 2021-12-31	pass
statement vs summary · net assets	consolidated 2022-12-31	pass
statement vs summary · net assets	non_consolidated 2020-12-31	pass
statement vs summary · net assets	non_consolidated 2021-12-31	pass
statement vs summary · net assets	non_consolidated 2022-12-31	pass
statement vs summary · net income attributable to parent	consolidated 2021-01-01/2021-12-31	pass
statement vs summary · net income attributable to parent	consolidated 2022-01-01/2022-12-31	pass
statement vs summary · operating cash flow	consolidated 2021-01-01/2021-12-31	pass
statement vs summary · operating cash flow	consolidated 2022-01-01/2022-12-31	pass
statement vs summary · revenue	consolidated 2021-01-01/2021-12-31	pass
statement vs summary · revenue	consolidated 2022-01-01/2022-12-31	pass
statement vs summary · revenue	non_consolidated 2021-01-01/2021-12-31	pass
statement vs summary · revenue	non_consolidated 2022-01-01/2022-12-31	pass
statement vs summary · total assets	consolidated 2021-12-31	pass
statement vs summary · total assets	consolidated 2022-12-31	pass
statement vs summary · total assets	non_consolidated 2021-12-31	pass
statement vs summary · total assets	non_consolidated 2022-12-31	pass